Bayesian population analysis of a harmonized physiologically based pharmacokinetic model of trichloroethylene and its metabolites.

Bayesian population analysis of a harmonized physiologically based pharmacokinetic (PBPK) model for trichloroethylene (TCE) and its metabolites was performed. In the Bayesian framework, prior information about the PBPK model parameters is updated using experimental kinetic data to obtain posterior parameter estimates. Experimental kinetic data measured in mice, rats, and humans were available for this analysis, and the resulting posterior model predictions were in better agreement with the kinetic data than prior model predictions. Uncertainty in the prediction of the kinetics of TCE, trichloroacetic acid (TCA), and trichloroethanol (TCOH) was reduced, while the kinetics of other key metabolites dichloroacetic acid (DCA), chloral hydrate (CHL), and dichlorovinyl mercaptan (DCVSH) remain relatively uncertain due to sparse kinetic data for use in this analysis. To help focus future research to further reduce uncertainty in model predictions, a sensitivity analysis was conducted to help identify the parameters that have the greatest impact on various internal dose metric predictions. For application to a risk assessment for TCE, the model provides accurate estimates of TCE, TCA, and TCOH kinetics. This analysis provides an important step toward estimating uncertainty of dose-response relationships in noncancer and cancer risk assessment, improving the extrapolation of toxic TCE doses from experimental animals to humans.

[1]  B C Allen,et al.  Pharmacokinetic modeling of trichloroethylene and trichloroacetic acid in humans. , 1993, Risk analysis : an official publication of the Society for Risk Analysis.

[2]  Fredrik U. Jönsson,et al.  Physiologically based pharmacokinetic modeling of inhalation exposure of humans to dichloromethane during moderate to heavy exercise. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.

[3]  C Eric Hack,et al.  Bayesian analysis of physiologically based toxicokinetic and toxicodynamic models. , 2006, Toxicology.

[4]  Harvey J Clewell,et al.  Revised assessment of cancer risk to dichloromethane: part I Bayesian PBPK and dose-response modeling in mice. , 2006, Regulatory toxicology and pharmacology : RTP.

[5]  Harvey J Clewell,et al.  A consistent approach for the application of pharmacokinetic modeling in cancer and noncancer risk assessment. , 2001, Environmental health perspectives.

[6]  M. Templin,et al.  Relative formation of dichloroacetate and trichloroacetate from trichloroethylene in male B6C3F1 mice. , 1993, Toxicology and applied pharmacology.

[7]  F Y Bois,et al.  Statistical analysis of Fisher et al. PBPK model of trichloroethylene kinetics. , 2000, Environmental health perspectives.

[8]  M S Prout,et al.  Species differences in response to trichloroethylene. I. Pharmacokinetics in rats and mice. , 1985, Toxicology and applied pharmacology.

[9]  H J Clewell,et al.  Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment. , 2000, Environmental health perspectives.

[10]  J W Fisher,et al.  Physiologically based pharmacokinetic models for trichloroethylene and its oxidative metabolites. , 2000, Environmental health perspectives.

[11]  J W Fisher,et al.  In vitro to in vivo extrapolation for trichloroethylene metabolism in humans. , 1998, Toxicology and applied pharmacology.

[12]  R. Tardif,et al.  Effect of various exposure scenarios on the biological monitoring of organic solvents in alveolar air , 1993, International archives of occupational and environmental health.

[13]  R. Tardif,et al.  Effect of various exposure scenarios on the biological monitoring of organic solvents in alveolar air , 1995, International archives of occupational and environmental health.

[14]  D. Henschler,et al.  Metabolism of trichloroethylene in man , 2004, Archives of Toxicology.

[15]  M E Andersen,et al.  Physiologically based pharmacokinetic modeling with trichloroethylene and its metabolite, trichloroacetic acid, in the rat and mouse. , 1991, Toxicology and applied pharmacology.

[16]  R. D. Stewart,et al.  Experimental human exposure to trichloroethylene. , 1970, Archives of environmental health.

[17]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[18]  F Y Bois,et al.  Statistical issues in toxicokinetic modeling: a bayesian perspective. , 2000, Environmental health perspectives.

[19]  Fredrik U. Jönsson,et al.  Bayesian estimation of variability in adipose tissue blood flow in man by physiologically based pharmacokinetic modeling of inhalation exposure to toluene. , 2001, Toxicology.

[20]  A. Gelman,et al.  Physiological Pharmacokinetic Analysis Using Population Modeling and Informative Prior Distributions , 1996 .

[21]  Bradley P. Carlin,et al.  BAYES AND EMPIRICAL BAYES METHODS FOR DATA ANALYSIS , 1996, Stat. Comput..

[22]  Ulrike Bernauer,et al.  Biotransformation of trichloroethene: dose-dependent excretion of 2,2,2-trichloro-metabolites and mercapturic acids in rats and humans after inhalation , 1996, Archives of Toxicology.

[23]  D. Henschler,et al.  Metabolism of trichloroethylene in man , 2004, Archives of Toxicology.

[24]  A. Monster,et al.  Kinetics of trichloroethylene in repeated exposure of volunteers , 1979, International archives of occupational and environmental health.

[25]  J W Fisher,et al.  A physiologically based pharmacokinetic model for trichloroethylene and its metabolites, chloral hydrate, trichloroacetate, dichloroacetate, trichloroethanol, and trichloroethanol glucuronide in B6C3F1 mice. , 1997, Toxicology and applied pharmacology.

[26]  W. S. Snyder,et al.  Report of the task group on reference man , 1979, Annals of the ICRP.

[27]  Sylvia Richardson,et al.  Inference and monitoring convergence , 1995 .

[28]  P. Åstrand,et al.  Textbook of Work Physiology , 1970 .

[29]  F. A. Smith,et al.  Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. , 1987, Toxicology and applied pharmacology.

[30]  J W Fisher,et al.  A human physiologically based pharmacokinetic model for trichloroethylene and its metabolites, trichloroacetic acid and free trichloroethanol. , 1998, Toxicology and applied pharmacology.

[31]  P. Bonate,et al.  Factors affecting species differences in the kinetics of metabolites of trichloroethylene. , 1995, Journal of toxicology and environmental health.

[32]  J. Larson,et al.  Species differences in the metabolism of trichloroethylene to the carcinogenic metabolites trichloroacetate and dichloroacetate. , 1992, Toxicology and applied pharmacology.

[33]  Sylvia Richardson,et al.  Markov Chain Monte Carlo in Practice , 1997 .

[34]  G. Johanson,et al.  Physiologically based modeling of the inhalation kinetics of styrene in humans using a bayesian population approach. , 2002, Toxicology and applied pharmacology.

[35]  T. Louis,et al.  Bayes and Empirical Bayes Methods for Data Analysis. , 1997 .

[36]  D. Henschler,et al.  Trichloroethylene exposure and trichloroethylene metabolites in urine and blood , 2004, Archiv für Toxikologie.

[37]  Jeffery M. Gearhart,et al.  A Partition Coefficient Determination Method for Nonvolatile Chemicals in Biological Tissues , 1994 .